OncoMatch/Clinical Trials/NCT06656598
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
Is NCT06656598 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Carboplatin and Paclitaxel for stage iii nsclc.
Treatment: Carboplatin · Paclitaxel · Cemiplimab · Cemiplimab (maintenance) — The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression (testing required; no eligibility threshold specified)
Expression of PD-L1 as assessed locally by the investigator center
Excluded: EGFR activating mutation
Known activating EGFR mutation
Excluded: ALK fusion
ALK ... translocation
Excluded: ROS1 fusion
ROS1 translocation
Disease stage
Required: Stage IIIA, IIIB, IIIC
Excluded: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
PS 0 to 1 (≥ 70 years), PS 0 to 1 (charlson ≥ 3 if < 70), PS upper 2 [excluded]
Prior therapy
Cannot have received: anti-PD-1 therapy
Previously received a treatment with anti-PD1/PDL1
Cannot have received: anti-PD-L1 therapy
Previously received a treatment with anti-PD1/PDL1
Cannot have received: anti-CTLA-4 therapy
Previously received a treatment with anti-CTLA
Cannot have received: chemotherapy
Previously received a treatment with ... chemotherapy for NSCLC
Cannot have received: immunotherapy
Previously received a treatment with ... immunotherapy ... for NSCLC
Cannot have received: thoracic radiotherapy
History of thoracic radiotherapy
Lab requirements
Blood counts
absolute neutrophil count (ANC) ≥ 1.5x10^9/L, platelets ≥ 100x10^9/L, hemoglobin ≥ 9 g/dl
Kidney function
estimated creatinine clearance ≥ 45 ml/min
Liver function
bilirubin ≤1.5xULN, AST ALT ≤3xULN, Albumin ≥28g/dl
Bone marrow function: ANC ≥ 1.5x10^9/L, platelets ≥ 100x10^9/L, hemoglobin ≥ 9 g/dl. Renal and hepatic function: estimated creatinine clearance ≥ 45 ml/min, bilirubin ≤1.5xULN, AST ALT ≤3xULN, Albumin ≥28g/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06656598 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
Are patients with EGFR alterations eligible?
No. EGFR activating mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK fusion is an exclusion criterion.
What disease stage is eligible?
Stage IIIA or IIIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify